Barclays PLC Sells 30,086 Shares of STERIS plc (NYSE:STE)

Barclays PLC lowered its holdings in shares of STERIS plc (NYSE:STE) by 18.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,473 shares of the medical equipment provider’s stock after selling 30,086 shares during the quarter. Barclays PLC owned 0.13% of STERIS worth $31,645,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in STE. Wealth Enhancement Advisory Services LLC increased its stake in STERIS by 12.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 5,801 shares of the medical equipment provider’s stock worth $1,274,000 after acquiring an additional 661 shares during the last quarter. ORG Partners LLC bought a new position in shares of STERIS during the 2nd quarter valued at approximately $76,000. Blue Trust Inc. raised its holdings in STERIS by 1,985.7% during the 2nd quarter. Blue Trust Inc. now owns 1,168 shares of the medical equipment provider’s stock valued at $263,000 after buying an additional 1,112 shares during the period. Boston Trust Walden Corp lifted its position in STERIS by 2.0% in the second quarter. Boston Trust Walden Corp now owns 44,794 shares of the medical equipment provider’s stock worth $9,834,000 after buying an additional 880 shares during the last quarter. Finally, Raymond James & Associates lifted its position in STERIS by 1.3% in the second quarter. Raymond James & Associates now owns 789,139 shares of the medical equipment provider’s stock worth $173,248,000 after buying an additional 10,455 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on STE shares. JMP Securities reissued a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Finally, KeyCorp boosted their price objective on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $262.50.

Insiders Place Their Bets

In other news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.14% of the stock is owned by company insiders.

STERIS Stock Performance

Shares of NYSE:STE opened at $214.27 on Friday. The firm’s 50 day simple moving average is $221.14 and its 200-day simple moving average is $227.35. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. STERIS plc has a one year low of $197.82 and a one year high of $248.24. The firm has a market cap of $21.15 billion, a PE ratio of 48.91 and a beta of 0.83.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the business posted $2.03 EPS. STERIS’s quarterly revenue was up 7.3% on a year-over-year basis. As a group, equities analysts predict that STERIS plc will post 9.1 EPS for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.06%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.